Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
2.437
-0.063 (-2.52%)
Aug 14, 2025, 10:57 AM - Market open
Armata Pharmaceuticals Employees
Armata Pharmaceuticals had 60 employees as of December 31, 2024. The number of employees decreased by 6 or -9.09% compared to the previous year.
Employees
60
Change (1Y)
-6
Growth (1Y)
-9.09%
Revenue / Employee
$114,467
Profits / Employee
-$428,450
Market Cap
88.20M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 60 | -6 | -9.09% |
| Dec 31, 2023 | 66 | -9 | -12.00% |
| Dec 31, 2022 | 75 | 4 | 5.63% |
| Dec 31, 2021 | 71 | 9 | 14.52% |
| Dec 31, 2020 | 62 | 24 | 63.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARMP News
- 1 day ago - Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia - PRNewsWire
- 3 months ago - Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit - PRNewsWire
- 8 months ago - Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PRNewsWire